INT230405

From wiki-pain
Revision as of 23:32, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.35
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

intracellular (USP6NL) molecular_function (USP6NL) cellular_component (USP6NL)
biological_process (USP6NL)
USP6NL (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 9 5.00 Very Low Very Low Very Low
dexamethasone 7 5.00 Very Low Very Low Very Low
Spinal cord 2 5.00 Very Low Very Low Very Low
cva 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Multiple Myeloma 22 80.36 Quite High
Osteoporosis 46 66.28 Quite High
Burning Mouth Syndrome 8 49.68 Quite Low
Osteolysis 7 27.52 Quite Low
Hypercalcemia 9 10.96 Low Low
Disease 12 5.00 Very Low Very Low Very Low
Pain 5 5.00 Very Low Very Low Very Low
Toothache 2 5.00 Very Low Very Low Very Low
Xerostomia 2 5.00 Very Low Very Low Very Low
Gagging 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Test-retest reliability of the OHIP-NL and of its seven domains was assessed by calculating intraclass correlation coefficients (ICCs).
Localization (reliability) of OHIP-NL
1) Confidence 0.15 Published 2008 Journal BMC Oral Health Section Body Doc Link PMC2329613 Disease Relevance 0 Pain Relevance 0
Test-retest reliability of the total OHIP-NL as well as of its domains could be qualified as excellent.
Localization (reliability) of OHIP-NL
2) Confidence 0.13 Published 2008 Journal BMC Oral Health Section Body Doc Link PMC2329613 Disease Relevance 0 Pain Relevance 0
In this study, we report that bortezomib used alone and in combination with a glucocorticoid as front-line treatment in previously untreated, bisphosphonate-naïve patients stimulates bone formation not only as shown by an increase in bALP but also through the use of a novel bone marker, pro-collagen type I N-terminal propeptide (PINP) that is released as collagen is deposited and becomes insoluble during the formation of the organic bone matrix (34) and may, therefore, be a better marker for ongoing bone formation.
Localization (released) of N-terminal propeptide
3) Confidence 0.02 Published 2010 Journal European Journal of Haematology Section Body Doc Link PMC2970902 Disease Relevance 0.35 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox